Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

First patient recruited in phase II study of ASN-002 in combination with vismodegib

Aug. 14, 2020

Theralase re-initiates phase II study of TLD-1433 in Canada

Aug. 14, 2020

New PTP-2C inhibitors disclosed by Betta Pharmaceuticals

Aug. 14, 2020

Jiangsu Chia Tai Tianqing Pharmaceutical Group presents AKT inhibitors

Aug. 14, 2020

Exelixis synthesizes new AXL and/or MERTK inhibitors

Aug. 14, 2020

New MNK1 and MNK2 inhibitors identified at Novostar Pharmaceuticals

Aug. 14, 2020

Minghui Pharmaceutical discovers nucleoside derivatives

Aug. 14, 2020

Bio-Path begins dosing in amended stage 2 of phase II prexigebersen study in AML

Aug. 13, 2020

Treadwell initiates phase II study of CFI-400945 and durvalumab in TNBC

Aug. 13, 2020

First phase I study of ATG-017 approved in Australia

Aug. 13, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 16, 2026.
AAIC 2026: Age of amyloid is being joined by time of tau
BioWorld
The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...
Celia trial: data strong, analysts skeptical
BioWorld
Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 14, 2026
Voyager’s gene therapy reduces tau levels in AD models
BioWorld Science
At the Alzheimer’s Association International Conference, researchers from Voyager Therapeutics Inc. presented preclinical efficacy data for VY-1706, a blood-brain...